# US 11,111,262 B2 · C-mannoside compounds useful for the treatment of urinary tract infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,111,262 B2
- Document ID: US11111262B2
- Status: Granted
- Kind: B2
- Application number: 17/063,947
- Filed: 2020-10-06
- Published: 2021-01-21
- Granted: 2021-09-07
- Earliest claimed: 2018-07-10
- Assignees: GlaxoSmithKline Intellectual Property Development Limited; Fimbrion Therapeutics, Inc.
- Applicants: Glaxosmithkline Intellectual Property Development Limited; Fimbrion Therapeutics, Inc.
- Inventors: Michael Joseph Bishop; Eugene L. Stewart; Katherine Louisa Widdowson; James Walter Janetka; Laurel Kathryn McGrane
- Web page: https://patentgrep.com/patent/US11111262B2

## CPC

- C07D 309/10: Oxygen atoms
- C07H 7/04: Carbocyclic radicals
- A61K 31/351: not condensed with another ring
- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 31/04: Antibacterial agents
- C07D 301/10: with catalysts containing silver or gold
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are new C-mannoside compounds and compositions and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment diseases such as urinary tract infection.

## Claims

### Claim 1

A compound which is

### Claim 2 (depends on 1)

A pharmaceutical composition comprising the compound as recited in claim 1 together with a pharmaceutically acceptable carrier.

### Claim 3 (depends on 2)

A pharmaceutical composition as recited in claim 2 formulated for oral administration.

### Claim 4 (depends on 3)

The pharmaceutical composition as recited in claim 3, wherein said composition is chosen from a tablet and a capsule.